Cellebrite DI Ltd. $CLBT Shares Purchased by Praesidium Investment Management Company LLC

Praesidium Investment Management Company LLC grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 339.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,185,274 shares of the company’s stock after buying an additional 915,821 shares during the period. Cellebrite DI accounts for about 4.0% of Praesidium Investment Management Company LLC’s portfolio, making the stock its 9th biggest holding. Praesidium Investment Management Company LLC owned approximately 0.49% of Cellebrite DI worth $21,370,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Cellebrite DI by 16.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after buying an additional 24,881 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Cellebrite DI by 16.2% in the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after buying an additional 43,898 shares during the last quarter. Invesco Ltd. lifted its position in shares of Cellebrite DI by 6.4% in the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after buying an additional 209,473 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of Cellebrite DI in the second quarter valued at approximately $341,000. Finally, Marshall Wace LLP acquired a new stake in shares of Cellebrite DI in the second quarter valued at approximately $4,472,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CLBT. Needham & Company LLC cut their price objective on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, DA Davidson began coverage on Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Cellebrite DI Stock Performance

Shares of NASDAQ CLBT opened at $12.84 on Friday. The firm has a market cap of $3.20 billion, a P/E ratio of 45.86, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. Cellebrite DI Ltd. has a 1-year low of $11.02 and a 1-year high of $19.98. The business’s 50 day moving average is $13.23 and its 200-day moving average is $15.05.

Insider Buying and Selling at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 13,269 shares of company stock worth $169,592 in the last 90 days. 5.70% of the stock is currently owned by company insiders.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.